CXCR4 and acute myeloid leukemia: Uproleselan entered Phase 3 clinical trials in 2019 (NCT03616470) in combination with chemotherapy to treat 380 patients with relapsed/refractory acute myeloid leukaemia (AML).199 Another compound from the same company (GMI-1359) has been developed as a dual inhibitor of both E-selectin and CXCR4, and is being investigated as an adjuvant to taxane-based therapy to reduce bone metastases in men with castration-resistant prostate cancer.200